CAPTAIN trial: TULSA shows zero blood loss, shorter stay vs robotic prostatectomy (p<0.001)

Profound Medical Corp.

Median blood loss 0 mL (TULSA) vs 100 mL (RP); length of stay 0.29 vs 1.24 days (p<0.001).
Significantly lower post-operative pain (NRS) through day 6 and higher overall health (EQ-5D-5L VAS) for 30 days (p<0.05).
Fewer TULSA patients reported extreme problems in mobility (0% vs 12%), self-care (3% vs 17%), usual activities (17% vs 40%) in first month.
First Level 1 RCT comparing TULSA to radical prostatectomy; 201 patients randomized across 23 sites.
CEO notes data supports insurance coverage decisions; company expects further follow-up reporting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.